LOUISVILLE, K.Y.—PGXL Laboratories, a provider ofpharmacogenetic testing and interpretive services, recently announced that ithas established a collaborative partnership with AutoGenomics Inc., a developerof an automated, microarray-based multiplexing diagnostic platform, whereinthey will utilize this platform—the automated INFINITI analyzer—for severaldifferent personalized medicine applications.PGXL plans to utilize the INFINITI Warfarin and CYP450 2C19Assay and the INFINITI KRAS-BRAF test. PGXL Labs was the first CLIA-certified lab in the country toconduct pharmacogenetic tests. It provides pharmacogenetic testing and interpretiveservices and developed one of the first commercial CYP2C9/VKORC1 tests foraccurate anticoagulant dosing. Along with its clinical practice, PGXL performscontract research for manufacturers of pharmaceuticals and medical equipment.
"The automation provided by the AutoGenomics' INFINITIAnalyzer will enhance workflow in our laboratories," said Mark Linder,executive vice president of operations and co-founder of PGXL Labs, in astatement. "With their comprehensive menu of molecular applications in thepharmacogenetics arena, we have found AutoGenomics to be a very suitablepartner in meeting our emerging testing needs."
A privately held company based in Vista, Calif.,AutoGenomics' technology can be used to assess disease signatures with novel genomicand proteomic markers in the area of genetic disorders, infectious disease,cancer and pharmacogenetics.
"We are excited to partner with PGXL Labs, who havepioneered in bringing the benefits of pharmacogenetics testing to patientsacross the country," stated Ramanath Vairavan, senior vice president ofAutoGenomics. "The versatility of our BioFilmChip Microarray technology allowsus to rapidly develop new test applications to meet the evolving needs incompanion diagnostic testing and enable PGXL Labs to expand the array of personalizedmedicine tests."
